Imugene Advances to Phase 2 in Gastric Cancer Trial
Filed with ASX · · 4 pages · English
In the deck
Earlier from Imugene
- Imugene Receives $1.85 million R&D Tax Incentive
- Imugene commences cGMP manufacture of PD-1 cancer vaccine
- Imugene Completes Phase 1b Cancer Vaccine Trial Recruitment
- Appendix 4E and Audited Financial Report
- PD-1 cancer vaccine development update
Later from Imugene
- IMU Meets Endpoints in Phase 1b Gastric Cancer Trial
- Pause in Trading
- IMU Announces Presentations on KEY-Vaxx and B-Vaxx at AACR
- Imugene doses first patient in HER-Vaxx phase 2 trial
- IMU Pre-IND FDA Meeting Provides Guidance for KEY-Vaxx
Follow Imugene into a list and get an email when it puts out news.
Follow Imugene